<DOC>
	<DOCNO>NCT02423239</DOCNO>
	<brief_summary>This study trial dexanabinol patient advance tumour . The purpose protocol study different dos study drug determine maximum safe dose drug give combination standard chemotherapy understand safety study drug measure reduction size patient ' cancer tumour ( ) . Dexanabinol synthetic cannabinoid previously undergone clinical trial traumatic brain injury ( TBI ) subject undergoing coronary artery bypass surgery . Currently dexanabinol investigation potential anti-tumour activity patient advance tumour .</brief_summary>
	<brief_title>A Study Dexanabinol Combination With Chemotherapy Patients With Advanced Tumours</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>HU 211</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Inclusion Criteria 1 . ( ) Parts 1 2b ( dexanabinol combination ) : Patients select histologically , cytologically radiologically confirm tumour advance , metastatic and/or progressive , eligible 1st line chemotherapy . HCC : patient ChildPugh A stage . Pancreatic cancer : patient diagnose adenocarcinoma ( i.e . pancreatic cancer patient islet cell neuroplasms exclude ) . ( ii ) Part 2a ( dexanabinol monotherapy ) : Patients histologically , cytologically radioloigically confirm tumour advance , metastatic and/or progressive , effective standard therapy available . Pancreatic cancer : patient diagnose adenocarinoma ( i.e . pancreatic cancer patient islet cell neuroplasms exclude ) . 2 . Adults patient define age ≥ 18 year . 3 . Eastern Collaborative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . 4 . Any acute chronic adverse effect prior chemotherapy radiotherapy resolve &lt; Grade 2 determine CTCAE v4.03 criterion , exception alopecia . 5 . ( ) Parts 1 2b : Measureable disease assess appropriate method tumour type e.g . RECIST 1.1 ( Eisenhauer , et al . 2009 ) . ( ii ) Part 2a : Evaluable disease , either measureable imaging , informative tumour marker ( ) . 6 . Laboratory value Screening : Absolute neutrophil count ≥ 1.5 x 109L ; Platelets ≥ 100 x 109/L ; Total bilirubin ; 1st line pancreatic cancer ( part 1 2b ) ≤1.25 time upper limit normal ( ULN ) ; tumour type setting except HCC ≤1.5 time ULN ; HCC ≤5 time ULN AST ( SGOT ) ≤2.5 time ULN ( liver tumour involvement ) 5 time ULN ( patient liver tumour involvement ) ; ALT ( SGPT ) ≤2.5 time ULN ( liver tumour involvement ) 5 time ULN ( patient liver tumour involvement ) ; Estimated GFR &gt; 50 mL/min ( base Wright formula ( Wright , et al . 2001 ) ; Negative hCG test woman childbearing potential 7 . Have life expectancy &gt; 3 month . 8 . Ability give write , informed consent prior studyspecific Screening procedure , understand consent may withdraw patient time without prejudice . 9 . Be willing able comply study protocol procedure . Exclusion Criteria 1 . Patient pregnant breast feeding . 2 . History clinically significant cardiac condition , include ischemic cardiac event , myocardial infarction unstable cardiac disease within 3 month Cycle 1 , Day 1 . 3 . Known brain metastasis . 4 . ( ) Parts 1 2b ( dexanabinol combination ) : Prior systemic chemotherapy . ( ii ) Part 2a ( dexanabinol monotherapy ) : Chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior Cycle 1 , Day 1 solid tumour ( exception hydroxyurea , must discontinue least 24 hour prior Cycle 1 , Day 1 ) . Localised palliative radiotherapy permit symptom control . 5 . Major surgery within 4 week prior Cycle 1 , Day 1 ; bone marrow transplant within 100 day prior Cycle 1 , Day 1 . 6 . Known human immunodeficiency virus positivity . 7 . Active hepatitis B C active liver disease ( malignancy ) ( applies tumours type enrol except HCC ) . 8 . Use investigational agent within 4 week Cycle 1 , Day 1 . 9 . Any active , clinically significant , viral , bacterial , systemic fungal infection within 4 week prior Cycle 1 , Day 1 . 10 . History significant chronic recurrent infection require treatment uncontrolled intercurrent illness would jeopardize patient safety , interfere objective protocol , limit patient compliance study requirement , determine Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>